Answers are grounded in this paper and cite their sources.
Bioinformatic analysis reveals a seven-gene senescence signature predicts survival and immunotherapy response in cervical cancer, highlighting potential for personalized treatment.
Cervical cancer (CESC) is a common malignancy in women. The senescence-associated secretory phenotype (SASP) contributes to tumor progression. We developed and validated a 7-gene SASP-related prognostic signature (PTPRB, RBM38, WNT3A, TNF, SPP1, ROR1, and MEIS2) using TCGA and GEO datasets. Patients in the low-risk group exhibited a more favorable prognosis and distinct immune infiltration patterns. TIDE analysis indicated a more favorable predicted immunotherapy response in the low-risk group. Single-cell analysis demonstrated distinct expression patterns of prognostic genes across cell types. This signature may help predict prognosis and therapeutic response in CESC patients.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: